JPMorgan analyst Anupam Rama noted that Sarepta announced updated data for the ongoing SRP-9003 phase 1/2a gene therapy program in limb-girdle muscular dystrophy type 2E in conjunction with the 2019 World Muscle Congress. The newly presented functional data includes signs of stability or improvement in all patients across all functional measures, noted Rama, who said the data hit his "base case/win scenario." The analyst, who sees the LGMD2E update as "a nice first step to helping improve sentiment" on the stock, keeps an Overweight rating on Sarepta shares.